Top and Current
Source: (remove) : David Risinger
RSSJSONXMLCSV
Top and Current
Source: (remove) : David Risinger
RSSJSONXMLCSV
Tue, August 6, 2024
Wed, July 24, 2024
Tue, April 16, 2024
Wed, October 11, 2023
Mon, July 10, 2023
Fri, February 10, 2023
Wed, February 8, 2023
Thu, February 2, 2023
Tue, January 17, 2023
Thu, December 22, 2022
Thu, November 17, 2022
Fri, September 30, 2022
Mon, May 23, 2022
Fri, April 30, 2021
Wed, March 10, 2021
Fri, February 26, 2021
Thu, January 28, 2021
Fri, November 13, 2020
Thu, August 20, 2020
Mon, May 11, 2020
Thu, April 2, 2020
Wed, April 1, 2020
Fri, February 14, 2020
Wed, February 12, 2020
Tue, February 11, 2020
Mon, September 30, 2019
Thu, September 5, 2019
Mon, July 15, 2019
Wed, March 6, 2019
Fri, December 14, 2018
Mon, November 5, 2018
Wed, October 3, 2018
Fri, August 3, 2018
Mon, July 23, 2018
Thu, June 21, 2018
Mon, May 7, 2018
Mon, March 19, 2018
Fri, February 23, 2018
Fri, December 15, 2017
Wed, November 29, 2017
Fri, November 3, 2017
Thu, October 5, 2017
Mon, August 7, 2017
Wed, November 16, 2016
Tue, May 3, 2016
Tue, September 1, 2015
Wed, July 29, 2015
Thu, March 12, 2015
Fri, October 31, 2014
Fri, March 14, 2014
Tue, October 1, 2013
Mon, August 5, 2013
Wed, July 31, 2013
Thu, January 10, 2013
Tue, November 27, 2012
Tue, May 29, 2012

David Risinger Downgraded (TBPH) to Hold and Decreased Target to $10 on, Aug 6th, 2024


Published on 2024-10-28 13:14:53 - WOPRAI, David Risinger
  Print publication without navigation


David Risinger of Leerink Partners, Downgraded "Theravance Biopharma, Inc." (TBPH) to Hold and Decreased Target from $15 to $10 on, Aug 6th, 2024.

David has made no other calls on TBPH in the last 4 months.



There is 1 other peer that has a rating on TBPH. Out of the 1 peers that are also analyzing TBPH, 0 agree with David's Rating of Hold.



This is the rating of the analyst that currently disagrees with David


  • Julian Harrison of "BTIG" Initiated at Strong Buy and Held Target at $21 on, Friday, April 12th, 2024